Latest Articlesddd

Is Prohost Still Cautious About Investing in Clovis Oncology?

September 12, 2016 0

The FDA announced what made Clovis Oncology (CLVS) shareholders believe that the bad times might have …

Xoma: Why this Firm’s Upcoming Conference Call Is Very Important

September 9, 2016 0

Xoma’s (XOMA) webcast and conference call scheduled for September 15, 2016, at 1:30 p.m. PDT (4:30 …

Nektar Therapeutics: Crossing the Barriers and Sailing into the Future

September 6, 2016 0

Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product …

Has the Time Come for Array Biopharma to Start Rallying?

August 31, 2016 0

At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good …

About Nymox Pharmaceutical Drug Fexapotide for the Prevention of Prostate Cancer

August 25, 2016 0

Benign Prostate Hypertrophy (BPH) Is Fexapotide the Safest and Effective Prostate Cancer Preventative? That’s what Nymox …

Learning from Pfizer Acquisition. Regeneron to Fight Zika and More

August 23, 2016 0

Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors …

A New Option for Osteoporosis Treatment That Would Prevent Bone Fractures

August 23, 2016 0

AMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is Radius …

Is Advaxis Finally Running on the Right Track?

August 18, 2016 0

Advaxis (ADXS) is a small clinical-stage biotech producing and developing cancer immunotherapy products based on its …

Radius Health: A New Osteoporosis Drug That Might Prevent Bone Fracture?

August 18, 2016 0

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is …

Why Portola Is Still Favorite

August 18, 2016 0

What’s Going on the Morning of Thursday, August 18, 2016? PORTOLA Portola Pharmaceuticals (PTLA) announced the …

Gilead and Genmab Agreement. A Quick Look at Moderna

August 15, 2016 0

GILEAD & GENMAB To Access Genmab’s (GEN) bispecific antibody technology, Gilead (GILD) signed a new agreement …

Editas, Adverum and Spark: Novel Gene Editing and Viral Vectors Make Gene Therapy Achievable

August 12, 2016 0

Gene Editing EDITAS MEDICINE CRISPR gene editing firm Editas Medicine (EDIT) signed a collaboration agreement with …

Sequenom: The Meaning of Becoming Part of LabCorp Holding

August 11, 2016 0

Sequenom (SQNM) is no more there as a separate biotech company, as it is on its …

Biotech Firms with Approaches Born To Stay and Succeed

August 10, 2016 0

Immunotherapy Engineered T-Cell Therapy Is Here to Stay Articles aimed at undermining the value of the …

Array: Selumetinib Negative Results Are No Match to Its Binimetinib Positive Results

August 9, 2016 0

We do expect some selling of Array today after AstraZeneca’s announced negative results from Phase 3 …

Why BMY News Is Not As Bad As Hysterical Investors Believed

August 5, 2016 0

ANOTHER MISLEADING STORY  This article was corrected after being posted. Read our apology at the end …

Plummeted Firms That Offer Good Investment Opportunities Are Filling the Place

August 3, 2016 0

Investors in the stock market know that stocks yo-yo all the time. Sometimes, the yo-yoing becomes …

Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

August 1, 2016 0

EMA’s created Priority Medicines (PRIME) regulatory initiative for products which the European agency rules they are …

Answering Readers Questions About the Possible Outcome of Valeant Pharmaceuticals’ Psoriasis Drug

July 19, 2016 0

The FDA advisory committee members’ inability to rule for or against the approval of Valeant (VRX) …

Coming from AstraZeneca and Juno: News That Makes a Big Difference

July 18, 2016 0

Important news is the news that informs about successful achievements that make a difference in treating …